Accarent’s new agreement with Stanford Health Care will cover revolutionary CAR T-cell therapy to treat leukemia, lymphoma, and multiple myeloma.

Through a new agreement with Stanford Health Care, Accarent Health continues to expand its bundled rate offering of the most complex and costly gene therapies, CAR T-cell therapy, through bundled episodes of care. Nationally, it is estimated there will be a $25B impact on payers within the next four years, with 95,000 individuals becoming eligible for gene or cell therapy by 2025.

Chimeric antigen receptor (CAR) T-cell therapy alters the genes inside immune cells (T-cells) to fight cancer so they can find and destroy cancer cells. This therapy is unique because it utilizes the patient’s T-cells, so there is no risk of rejection, unlike solid organ or allogeneic stem cell transplant. CAR T-cell therapies are used to treat some kinds of lymphomas, leukemias, and multiple myeloma and are typically used after other types of treatment have been tried. Through this partnership, Accarent will provide access to Novartis Kymriah, Kite Yescarta, Kite Tecartus, Juno Brenyanzi, and Bluebird Abecma to treat acute lymphocytic leukemia, B-cell lymphoma, Large B-cell Lymphoma, mantle cell lymphoma, and multiple myeloma.

Accarent Health’s gene therapy program limits risk for the employer through transparent bundled costs and use of only top quality providers and ensures patients are receiving the best possible care, often with no copays or out-of-pocket expenses. In addition to providing defined episodes of care for this lifesaving treatment, certified nurse case managers and concierges make up the Accarent Care Team, who help the patient navigate the process, answer any questions, coordinate care with providers, and assist with lodging and transportation.

Employers interested in adopting a value-based health care strategy can learn more about Accarent Health at www.accarenthealth.com.